Identification of Bio-Markers Predicting the Therapeutic Effects of Tocilizumab in Rheumatoid Arthritis

Identification of Bio-Markers Predicting the Therapeutic Effects of Tocilizumab in Rheumatoid Arthritis - Identification of Bio-Markers Predicting the Therapeutic Effects of Tocilizumab in Rheumatoid Arthritis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012005

Enrollment

Registered

2013-10-09

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients refractory to conventinal therapies for rheumatoid arthritis

Exclusion criteria

Exclusion criteria: Patients with interstitial pneumonia or renal dysfunction

Design outcomes

Primary

Measure	Time frame
The therapeutic effects 52 weeks after the initiation of tocilizumab	—

Secondary

Measure	Time frame
Biomarkers such as c-reactive protein, matrix metalloproteinase, cytokines before and after tocilizumab therapy	—

Countries

Japan

Contacts

Public ContactTohru Takeuchi

Osaka Medical College Department of Internal Medicine (I)

t-takeuchi@osaka-med.ac.jp072-683-1221

Outcome results